Compare Stocks: RARE, ABVX, PRAX, and PTGX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVX Abivax	$114.95 -2.7%	$122.76	$69.81 ▼ $148.83	$10.03B	1.03	880,182 shs	986,993 shs
PRAX Praxis Precision Medicines	$375.84 +3.1%	$325.63	$37.19 ▼ $392.70	$10.50B	2.78	442,788 shs	413,317 shs
PTGX Protagonist Therapeutics	$154.32 +2.4%	$134.70	$54.50 ▼ $160.81	$9.99B	1.78	488,124 shs	402,517 shs
RARE Ultragenyx Pharmaceutical	$25.83 +2.0%	$28.58	$18.29 ▼ $39.89	$2.55B	0.35	2.11 million shs	2.39 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVX Abivax	0.00%	-3.37%	-12.36%	-5.77%	+59.90%
PRAX Praxis Precision Medicines	0.00%	+2.46%	+16.58%	+9.40%	+730.59%
PTGX Protagonist Therapeutics	0.00%	-0.50%	+13.95%	+55.58%	+174.44%
RARE Ultragenyx Pharmaceutical	0.00%	-2.49%	-4.40%	+10.43%	-12.02%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVX Abivax	$114.95 -2.7%	$122.76	$69.81 ▼ $148.83	$10.03B	1.03	880,182 shs	986,993 shs
PRAX Praxis Precision Medicines	$375.84 +3.1%	$325.63	$37.19 ▼ $392.70	$10.50B	2.78	442,788 shs	413,317 shs
PTGX Protagonist Therapeutics	$154.32 +2.4%	$134.70	$54.50 ▼ $160.81	$9.99B	1.78	488,124 shs	402,517 shs
RARE Ultragenyx Pharmaceutical	$25.83 +2.0%	$28.58	$18.29 ▼ $39.89	$2.55B	0.35	2.11 million shs	2.39 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVX Abivax	0.00%	-3.37%	-12.36%	-5.77%	+59.90%
PRAX Praxis Precision Medicines	0.00%	+2.46%	+16.58%	+9.40%	+730.59%
PTGX Protagonist Therapeutics	0.00%	-0.50%	+13.95%	+55.58%	+174.44%
RARE Ultragenyx Pharmaceutical	0.00%	-2.49%	-4.40%	+10.43%	-12.02%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABVX Abivax	2.80	Moderate Buy	$156.50	36.15% Upside
PRAX Praxis Precision Medicines	3.00	Buy	$585.95	55.90% Upside
PTGX Protagonist Therapeutics	2.94	Moderate Buy	$140.53	-8.93% Downside
RARE Ultragenyx Pharmaceutical	2.84	Moderate Buy	$58.89	127.99% Upside

Current Analyst Ratings Breakdown

Latest RARE, ABVX, PRAX, and PTGX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2026	PRAX Praxis Precision Medicines	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$470.00 ➝ $575.00
8/21/2026	RARE Ultragenyx Pharmaceutical	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$67.00 ➝ $74.00
8/20/2026	RARE Ultragenyx Pharmaceutical	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$81.00 ➝ $83.00
8/20/2026	RARE Ultragenyx Pharmaceutical	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$45.00 ➝ $58.00
8/20/2026	RARE Ultragenyx Pharmaceutical	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$45.00 ➝ $46.00
8/20/2026	RARE Ultragenyx Pharmaceutical	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$96.00 ➝ $103.00
8/17/2026	PRAX Praxis Precision Medicines	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$945.00
8/17/2026	PTGX Protagonist Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$112.00 ➝ $178.00
8/11/2026	PTGX Protagonist Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C+)
8/10/2026	PTGX Protagonist Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$145.00 ➝ $170.00
8/10/2026	PTGX Protagonist Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$118.00 ➝ $173.00

(Data available from 8/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABVX Abivax	N/A	N/A	N/A	N/A	$6.57 per share	N/A
PRAX Praxis Precision Medicines	$8.55M	1,227.30	N/A	N/A	$48.03 per share	7.83
PTGX Protagonist Therapeutics	$46.02M	216.99	N/A	N/A	$13.01 per share	11.86
RARE Ultragenyx Pharmaceutical	$673M	3.78	N/A	N/A	($2.95) per share	-8.76

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABVX Abivax	-$380.27M	-$5.21	N/A	N/A	N/A	N/A	-99.02%	-70.26%	9/21/2026 (Estimated)
PRAX Praxis Precision Medicines	-$303.27M	-$12.93	N/A	N/A	N/A	N/A	-34.15%	-32.42%	11/4/2026 (Estimated)
PTGX Protagonist Therapeutics	-$130.15M	$1.03	149.83	N/A	N/A	29.40%	12.03%	11.23%	11/5/2026 (Estimated)
RARE Ultragenyx Pharmaceutical	-$575M	-$5.84	N/A	N/A	N/A	-81.79%	-1,024.42%	-44.40%	11/3/2026 (Estimated)

Latest RARE, ABVX, PRAX, and PTGX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	PRAX Praxis Precision Medicines	-$3.67	-$2.87	+$0.80	-$2.87	$1.25 million	N/A
8/5/2026	Q2 2026	PTGX Protagonist Therapeutics	$2.27	$2.29	+$0.02	$2.29	$212.03 million	$213.48 million
8/4/2026	Q2 2026	RARE Ultragenyx Pharmaceutical	-$1.22	-$0.90	+$0.32	-$0.90	$183.08 million	$214.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABVX Abivax	N/A	N/A	N/A	N/A	N/A
PRAX Praxis Precision Medicines	N/A	N/A	N/A	N/A	N/A
PTGX Protagonist Therapeutics	N/A	N/A	N/A	N/A	N/A
RARE Ultragenyx Pharmaceutical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABVX Abivax	N/A	8.25	8.25
PRAX Praxis Precision Medicines	N/A	15.73	15.73
PTGX Protagonist Therapeutics	N/A	21.71	21.71
RARE Ultragenyx Pharmaceutical	N/A	1.73	1.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABVX Abivax	47.91%
PRAX Praxis Precision Medicines	67.84%
PTGX Protagonist Therapeutics	98.63%
RARE Ultragenyx Pharmaceutical	97.67%

Insider Ownership

Company	Insider Ownership
ABVX Abivax	N/A
PRAX Praxis Precision Medicines	3.00%
PTGX Protagonist Therapeutics	5.19%
RARE Ultragenyx Pharmaceutical	5.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABVX Abivax	61	87.25 million	N/A	Not Optionable
PRAX Praxis Precision Medicines	110	27.92 million	27.08 million	Optionable
PTGX Protagonist Therapeutics	120	64.71 million	61.35 million	Optionable
RARE Ultragenyx Pharmaceutical	1,371	98.59 million	93.46 million	Optionable

RARE, ABVX, PRAX, and PTGX Headlines

Recent News About These Companies

Cantor Fitzgerald Sticks to Its Buy Rating for Ultragenyx Pharmaceutical (RARE)

August 23 at 10:00 AM | theglobeandmail.com

Wedbush Sticks to Its Hold Rating for Ultragenyx Pharmaceutical (RARE)

August 23 at 10:00 AM | theglobeandmail.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Expected to Rise, Morgan Stanley Analyst Says

August 23 at 1:48 AM | americanbankingnews.com

Wells Fargo & Company Forecasts Strong Price Appreciation for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock

August 22 at 4:35 AM | americanbankingnews.com

Cantor Fitzgerald Increases Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $103.00

August 22 at 2:58 AM | americanbankingnews.com

Citigroup Increases Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $58.00

August 22 at 2:24 AM | americanbankingnews.com

Ultragenyx: Progress Is Real, But Profitability Is The Real Test (Rating Upgrade)

August 21 at 12:27 PM | seekingalpha.com

Morgan Stanley Issues Positive Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price

August 21 at 8:59 AM | marketbeat.com

182,638 Shares in Ultragenyx Pharmaceutical Inc. $RARE Purchased by Blue Owl Capital Holdings LP

August 21 at 3:28 AM | marketbeat.com

Canaccord Genuity Group Forecasts Strong Price Appreciation for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock

August 20 at 3:59 PM | marketbeat.com

GSDIa Gene Therapy Approval Signals New Path for Rare Disease Manufacturing

August 20 at 3:33 PM | pharmtech.comP

Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease ...

August 20 at 3:33 PM | markets.businessinsider.com

Citigroup Raises Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $58.00

August 20 at 3:17 PM | marketbeat.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Given New $46.00 Price Target at Wells Fargo & Company

August 20 at 11:23 AM | marketbeat.com

RARE Stock Gains on FDA Nod for Rare Disease Gene Therapy Genglycos

August 20 at 11:21 AM | zacks.com

Pharmalittle: We’re reading about a Regeneron rare disease drug, an Ultragenyx gene therapy, and more

August 20 at 10:32 AM | statnews.comS

Ultragenyx Pharmaceutical Inc.: Ultragenyx Announces U.S. FDA Approval of GENGLYCOS Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause ...

August 20 at 10:32 AM | finanznachrichten.de

FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy

August 20 at 10:32 AM | yahoo.com

Ultragenyx’s Gene-Therapy Win Could Unlock A ‘Long Revenue Tailwind,’ Says Wells Fargo — This Analyst Sees 265% Upside For RARE Stock

August 20 at 10:32 AM | finance.yahoo.com

Ultragenyx's gene therapy wins first FDA approval for rare metabolic disorder

August 20 at 10:32 AM | msn.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Gap Up After Analyst Upgrade

August 20 at 10:19 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

RARE, ABVX, PRAX, and PTGX Company Descriptions

Abivax NASDAQ:ABVX

$114.95 -3.24 (-2.74%)

As of 08/21/2026 04:00 PM Eastern

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

Praxis Precision Medicines NASDAQ:PRAX

$375.84 +11.26 (+3.09%)

As of 08/21/2026 04:00 PM Eastern

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Protagonist Therapeutics NASDAQ:PTGX

$154.32 +3.63 (+2.41%)

As of 08/21/2026 04:00 PM Eastern

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Ultragenyx Pharmaceutical NASDAQ:RARE

$25.83 +0.51 (+2.01%)

As of 08/21/2026 04:00 PM Eastern

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RARE, ABVX, PRAX, and PTGX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RARE, ABVX, PRAX, and PTGX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RARE, ABVX, PRAX, and PTGX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RARE, ABVX, PRAX, and PTGX Company Descriptions

Abivax NASDAQ:ABVX

Praxis Precision Medicines NASDAQ:PRAX

Protagonist Therapeutics NASDAQ:PTGX

Ultragenyx Pharmaceutical NASDAQ:RARE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RARE, ABVX, PRAX, and PTGX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RARE, ABVX, PRAX, and PTGX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RARE, ABVX, PRAX, and PTGX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RARE, ABVX, PRAX, and PTGX Company Descriptions

Abivax NASDAQ:ABVX

Praxis Precision Medicines NASDAQ:PRAX

Protagonist Therapeutics NASDAQ:PTGX

Ultragenyx Pharmaceutical NASDAQ:RARE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools